Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Work In Process: 2021-2023

Historic Work In Process for Kiniksa Pharmaceuticals International (KNSA) over the last 1 years, with Dec 2023 value amounting to $18.3 million.

  • Kiniksa Pharmaceuticals International's Work In Process rose 189.26% to $18.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $18.3 million, marking a year-over-year increase of 189.26%. This contributed to the annual value of $18.3 million for FY2023, which is 189.26% up from last year.
  • According to the latest figures from Q4 2023, Kiniksa Pharmaceuticals International's Work In Process is $18.3 million, which was up 36.43% from $13.4 million recorded in Q3 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Work In Process peaked at $18.3 million during Q4 2023, and registered a low of $148,000 during Q1 2022.
  • For the 3-year period, Kiniksa Pharmaceuticals International's Work In Process averaged around $8.3 million, with its median value being $6.5 million (2022).
  • Data for Kiniksa Pharmaceuticals International's Work In Process shows a peak YoY soared of 9,033.11% (in 2023) over the last 5 years.
  • Quarterly analysis of 3 years shows Kiniksa Pharmaceuticals International's Work In Process stood at $4.2 million in 2021, then reached $6.3 million in 2022, then spiked by 189.26% to $18.3 million in 2023.
  • Its last three reported values are $18.3 million in Q4 2023, $13.4 million for Q3 2023, and $6.6 million during Q2 2023.